Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00274937 · OUTCOME

Predictive Value of the Detection of EBV DNA in the Peripheral Blood

Radiation Therapy, Amifostine, and Chemotherapy in Treating Young Patients With Newly Diagnosed Nasopharyngeal Cancer · Source last updated 2022-10-25

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
Not reported
Unit
Not reported
Interval / dispersion
Not reported
Time frame
Up to 6 years

What was measured

The prognostic value of the presence of EBV DNA will be assessed using the log-rank test, adjusted by initial stage of disease, if appropriate. The proposed analysis will take place at the analytic endpoint of the clinical trial.

Analysis population: Funding was not obtained and results will never be reported.

Groups in this outcome

Stratum II

AJCC Stage IIb - IV

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Stratum II0

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields
denoms
  1. counts
    1. group Id
      OG000
      value
      0
    units
    Participants
description
The prognostic value of the presence of EBV DNA will be assessed using the log-rank test, adjusted by initial stage of disease, if appropriate. The proposed analysis will take place at the analytic endpoint of the clinical trial.
groups
  1. description
    AJCC Stage IIb - IV
    id
    OG000
    title
    Stratum II
population Description
Funding was not obtained and results will never be reported.
reporting Status
POSTED
time Frame
Up to 6 years
title
Predictive Value of the Detection of EBV DNA in the Peripheral Blood
type
SECONDARY

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice